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Abstract
Borrelia burgdorferi, the pathogen of Lyme disease, cycles in nature through Ixodes ticks and mammalian hosts. At least five
Complement Regulator-Acquiring Surface Proteins (BbCRASPs) are produced by B. burgdorferi, which are thought to assist
spirochetes in host immune evasion. Recent studies established that BbCRASP-2 is preferentially expressed in mammals, and
elicits robust antibody response in infected hosts, including humans. We show that BbCRASP-2 is ubiquitously expressed in
diverse murine tissues, but not in ticks, reinforcing a role of BbCRASP-2 in conferring B. burgdorferi defense against
persistent host immune threats, such as complement. BbCRASP-2 immunization, however, fails to protect mice from B.
burgdorferi infection and does not modify disease, as reflected by the development of arthritis. An infectious BbCRASP-2
mutant was generated, therefore, to examine the precise role of the gene product in spirochete infectivity. Similar to wild
type B. burgdorferi, BbCRASP-2 mutants remain insensitive to complement-mediated killing in vitro, retain full murine
infectivity and induce arthritis. Quantitative RT-PCR assessment indicates that survivability of BbCRASP-2-deficient B.
burgdorferi is not due to altered expression of other BbCRASPs. Together, these results suggest that the function of a
selectively expressed B. burgdorferi gene, BbCRASP-2, is not essential for complement resistance or infectivity in the murine
host.
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Introduction
Borrelia burgdorferi is the causative agent of Lyme disease, the most
prevalent vector-borne disease in the United States and Europe
[1,2]. In nature, B. burgdorferi cycles between rodent reservoirs and
Ixodes scapularis ticks. This complex enzootic life cycle requires
successful colonization and coordinated transmission between
strikingly different host and vector environments. It is thought that
differential gene expression plays an important role in allowing the
spirochete to navigate the transitions between hosts and in
establishing persistent infection [3–6]. Due to the availability of
excellent murine models of Lyme disease, B. burgdorferi gene
expression through the tick-rodent transmission cycle can be
examined in the laboratory [7–11]. These efforts may provide
important clues for understanding functions of microbial gene
products that support B.burgdorferi persistencein nature [3–6,12,13].
The genes encoding the Complement Regulator-Acquiring
Surface Proteins (BbCRASPs) of B. burgdorferi are differentially
expressed in the pathogen life cycle [14,15]. As many as five
BbCRASPs were identified that bind host proteins of the factor H
(FH) family, and possibly contribute to the spirochete defense
against host complement-mediating killing[16–18]. BbCRASP-1
(also known as cspA or bba68) and BbCRASP-2 (also called cspZ or
bbh06), located on linear plasmids lp54 and lp28-3 respectively,
share little sequence homology with other BbCRASP sequences. In
contrast, BbCRASP-3, -4 and -5 are sequentially similar and belong
to the erp paralog family and are known as erpP (bbn38), erpC and
erpA (bbp38 and bbl39), respectively. Collectively these erp genes are
also known as ospE, and are encoded on multiple cp32 plasmids
[19–22]. The gene erpC (located on cp32-2) and one of the three
erpA genes (located on cp32-5) currently lack TIGR database
annotations, as the sequenced B31 M1 isolate lost these plasmids.
Of all the BbCRASP genes, BbCRASP-2 is the only gene without
paralogous family members, and is therefore unique in B.
burgdorferi [17].
Evasion of host complement is especially important for B.
burgdorferi, as it establishes an extracellular and disseminated
infection in many tissue environments where the complement
system is readily available through host vasculature or body fluids.
The complement system includes soluble membrane binding
proteins which, upon contact with foreign cells, become activated,
and are then capable of direct chemical lysis via membrane
disruption [23,24]. Specific regulatory proteins, such as FH family
proteins, protect the host from self-inflicted damage by preventing
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albicans, Neisseria meningiditis, and Streptococcus pneumonia have been
shown to bind host FH, and that FH binding in N. gonorrhea and B.
burgdorferi provides protection against complement killing in vitro
[25–29]. BbCRASPs have been identified according to their
ability to bind proteins of the FH family, although individual
BbCRASPs vary in their affinities for particular FH family
proteins. For example, only BbCRASP-1 and -2 preferentially
bind factor H-like protein (FHL-1), while BbCRASP-3, -4 and -5
selectively bind factor H-related protein (FHR-1) [17,30,31].
BbCRASPs also vary in their interaction with uncharacterized
serum proteins [14,32]. Though the binding affinities and the
expression profiles of the BbCRASPs have been studied, the
independent role of each BbCRASP in B. burgdorferi infectivity is
not clear. Recently studies using a non-infectious mutant
demonstrated that the loss of BbCRASP-1 sensitized the B.
burgdorferi to complement-mediated lysis in human serum, an effect
that can be rescued with gene complementation [25]. While there
is some disagreement as to the expression of BbCRASP-1 during
mammalian infection, RT-PCR analysis indicate that it is only
expressed transiently at the tick bite site and in ticks [14], but not
expressed in mice [33]. BbCRASP-1 therefore, may not play an
essential role in mammalian infection [33], but could be important
in spirochete survival in feeding ticks. Although the above set of
studies suggest an important role for BbCRASPs in spirochete
immune evasion, the precise role of individual BbCRASPs, or
their orchestrated role in the B. burgdorferi infection cycle is not
clear, largely because infectious BbCRASP-deficient B. burgdorferi
have not yet been successfully generated [14].
BbCRASP-2 is expressed by B. burgdorferi during murine infection
[14,34], and infected hosts, including human patients, readily
generate BbCRASP-2-specific antibodies [17,35]. This protein is
conserved among B. burgdorferi isolates [22], reported to be
localized on the spirochete surface [17] and has recently been
suggested as a possible target for a second generation Lyme disease
vaccine [17,35]. The previous studies also suggest a possible
functional role for BbCRASP-2 in immune evasion and pathogen
survival [17,22]. In order to test this hypothesis, we sought to
determine whether BbCRASP-2 is consistently produced in
diverse murine tissues throughout the infection, and whether
BbCRASP-2 immunization could provide host immunity and
influence disease outcome. To explore the precise role of
BbCRASP-2 in B. burgdorferi infectivity of a mammalian host, we
assessed how targeted deletion of BbCRASP-2 in an infectious
isolate influences B. burgdorferi infection in the murine model of
Lyme borreliosis. Functional characterization of microbial ligands
that are differentially expressed in the complex enzootic cycle of B.
burgdorferi is critical to understanding the adaptive strategies of a
pathogen that has evolved to persist in diverse tissue environments
resulting in multi-system disorders.
Materials and Methods
Bacteria, Mice and Ticks
Borrelia burgdorferi infectious isolate A3 [36], a clonal derivative of
B31 M1, was used throughout the study. Female C3H/HeN mice
between 4 and 6 weeks old purchased from the National Cancer
Institute. Mice were inoculated with a single subcutaneous
injection of 10
5 spirochetes per mouse. All animal procedures
were in compliance with the guidelines set by the Institutional
Animal Care and Use Committee. The ticks used in this study
belong to a colony that is reared and maintained in the laboratory
as described [37].
PCR
Micewere sacrificed following infection, and the heart, tibiotarsal
joint, and skin samples were removed and frozen in liquid nitrogen.
B. burgdorferi-infected ticks were isolated by allowing ticks to feed on
an infected murine host as described [37]. RNA was extracted using
TRIzol reagent (Invitrogen) and further treated with DNase I
(Invitrogen), and finally purified using the RNeasy kit (Qiagen).
RNA was used as a template for reverse-transcriptase polymerase
chain reaction (RT-PCR) using the AffinityScript cDNA synthesis
kit (Stratagene). The primers used for PCR reactions are indicated
in Supplementary Table S1. Quantitative PCR analysis was
performed using iQ SybrGreen Supermix (BioRad) as previously
described [13]. For quantitative analysis of gene expression, the
target transcripts were normalized to the number of flaB transcripts,
whereas for quantitative measurement of B. burgdorferi burden in
infected tissues, flaB transcripts were normalized to mouse or tick b-
actin levels. All quantitative PCR results were checked for specificity
by melting curve analysis.
Production of recombinant BbCRASP-2 protein and
BbCRASP-2 antibodies
Recombinant BbCRASP-2 protein was produced in E. coli using
the pET303/CT-His Champion vector (Invitrogen) using specific
primers (Supplementary Table S1). Recombinant BbCRASP-2 was
fused with a C-terminal 6-histidine tag for purification, and lacked
the peptides encoding the lipidation signal. Polyclonal antibodies
against recombinant BbCRASP-2 were generated in mice as
describedearlier[37,38].Briefly,recombinantBbCRASP-2(10mg/
animal) was emulsified in complete Freund’s adjuvant (Sigma) and
injected into groups of 10 mice. The animals were boosted twice at
10 days intervals with the same dose of antigen in incomplete
Freund’s adjuvant (Sigma) and the sera were collected two weeks
following the second boost. Titer and specificity of the serum was
tested by ELISA and immunoblot blot as described previously [39].
Proteinase K accessibility assay
Proteinase K accessibility assays were performed as described
[40]. Briefly, B. burgdorferi (2610
8) were gently washed three times
in 1 ml of PBS (pH 7.4) and collected by centrifugation at
4,0006g for 4 min. Washed spirochetes were then gently
resuspended in 1 ml of PBS and split into two equal 500 ml
volumes. One aliquot received 200 mg of proteinase K (PK)
(Sigma) while the other aliquot received an equal volume of PBS
without PK. Both aliquots were incubated for 1 h at room
temperature before the addition of 10 ml of phenylmethylsulfonyl-
fluoride (Sigma) to stop PK activity. Spirochete suspensions were
subsequently pelleted by centrifugation at 10,0006g for 10 min
and resuspended in PBS for immunoblot analysis using antibodies
against BbCRASP-2, FlaB, or OspA.
Active immunization and infection studies
Groups of mice (6 animals/group) were immunized with
adjuvant containing either recombinant BbCRASP-2, or adjuvant
containing the same volume of phosphate buffered saline (PBS) in
similar fashion as describe in above paragraph. Ten days after the
final boost, mice were infected with a subcutaneous injection of B.
burgdorferi (10
5 spirochetes/mouse). Mice were sacrificed after 7,
12, 15 and 30 days of infection. Heart, tibiotarsal joint, and skin
samples were collected and frozen in liquid nitrogen. RNA was
isolated from infected tissues and B. burgdorferi burden was
measured using quantitative PCR. B. burgdorferi-infected mice were
examined for swelling and histology of the tibiotarsal joints as
detailed [13,41,42].
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mutant
BbCRASP-2-deficient B. burgdorferi was generated by homologous
recombination replacing the entire open reading frame of the
BbCRASP-2 gene with a kanamycin resistance cassette
[13,38,39,43,44] using primers as indicated in Supplementary Table
S1. DNA fragments flanking the BbCRASP-2 open reading frame on
the 59 and 39 sides were PCR-amplified and inserted into the plasmid
pXLF10601. This plasmid was sequenced to confirm identity and
electroporated into wild-type B.burgdorferiA3, and transformants were
selected for growth in the presence of kanamycin. PCR analysis was
used to confirm the intended recombination event using primers P5-
P12. Immunoblotting analysis using BbCRASP-2 antibodies was
performed to confirm the loss of BbCRASP-2. The plasmid profile of
the mutant B. burgdorferi was assessed to confirm no loss of wild type
plasmids [13,38,44].
The serum sensitivity of the BbCRASP-2 mutant was measured
using a published procedure [16]. Briefly, triplicate samples of wild
type B. burgdorferi or isogenic BbCRASP-2 and BbCRASP-1 mutant
[25] were seeded into 1 ml tubes at a final concentration of 5610
6
bacteria per ml. These aliquots were incubated in either 50%
normal human serum or 50% heat-inactivated human serum. At
0, 1, 4, and 16 hours after the addition of serum, spirochete
viability was examined using dark-field microscopy. Normal
human serum (Sigma) collected from healthy, anonymous donors
with no reactivity to B. burgdorferi after chemiluminescent
immunoblot analyses were used in the assay.
To examine the phenotype of the BbCRASP-2 mutant in vivo, the
mutant and wild type B. burgdorferi were separately inoculated into
2 groups of mice (6 animals/group, 10
5 spirochetes/mouse). A skin
sample, the heart and the joints from infected mice were isolated at
day 7, 12 and 18 after challenge, and B. burgdorferi burdens were
measured by quantitative RT-PCR analysis. Before sacrifice, ear
and spleen tissues from the mice were cultured in BSK medium for
the presence of viable B. burgdorferi. Rear ankle joints of individual
mice were measured before infection and at 7, 12 and 18 days
after infection until sacrifice. Acquisition of wild type and mutant
B. burgdorferi by nymphal I. scapularis ticks was performed as
described earlier [37]. Briefly, groups of C3H mice (6 animals/
group) were infected with wild type or BbCRASP-2 mutant B.
burgdorferi (10
5 spirochetes/mouse). Following 12 days of infection,
25 I. scapularis nymphs were placed on each mouse. The ticks were
forcibly detached from the mice following repletion and
immediately stored in liquid nitrogen. B. burgdorferi burdens in
each tick sample were measured as described earlier by
quantitative RT-PCR analysis.
Statistical analysis
Results are expressed as the mean 6 standard error of the mean
(SEM). The significance of the difference between the mean values
of the groups was evaluated by two-tailed Student t test.
Results
BbCRASP-2 is ubiquitously expressed during murine
infection
To understand role of BbCRASP-2 in B. burgdorferi infectivity, we
first assessed the transcript levels of BbCRASP-2 in multiple murine
tissue locations where B. burgdorferi persists during infection, and in
various stages of infected ticks. C3H mice were infected with B.
burgdorferi, and heart, joints and skin samples were collected at days
5, 7, 12, 16, and 24 following infection. Larval and nymphal ticks
werefed on parallel groups of 15 day-infected mice(25ticks/mouse)
and fully engorged ticks were isolated following 3 days of repletion.
Batches of infected fed larvae were allowed to molt and then
collected as unfed nymphs. Total RNA was prepared from murine
andtick samples, and subjected toquantitative RT-PCRtomeasure
the B. burgdorferi BbCRASP-2 transcript levels. BbCRASP-2 is
ubiquitously and consistently expressed throughout infection
(Fig. 1A), but was undetectable in larval or nymphal ticks. As
reported earlier [17], the infected mice developed a specific
antibody response against BbCRASP-2 (data not shown).
BbCRASP-2 immunization failed to evoke protective
immunity in mice
Because BbCRASP-2 is surface-exposed [17], immunogenic,
and expressed throughout the murine infection, we next assessed if
immunization of mice using recombinant BbCRASP-2 could elicit
protective immunity and influence the outcome of Lyme disease.
To accomplish this, we produced recombinant BbCRASP-2 in E.
coli and immunized the murine host with purified BbCRASP-2.
Separate groups of C3H mice (6 animals/group) were immunized
with either BbCRASP-2 or PBS (control) mixed with similar
volume of adjuvant. ELISA (data not shown) and immunoblotting
performed after final boosting indicated that immunized mice had
developed strong antibody titer that specifically recognized
recombinant and native BbCRASP-2 (Fig. 2A). Although previous
immunofluorescence studies indicated that BbCRASP-2 antibod-
ies recognized native antigen on the surface of the intact
spirochetes [17], our proteinase K accessibility assay indicated
that BbCRASP-2 is not significantly exposed on the spirochete
surface (Fig. 2B). Ten days after the final immunization mice were
needle-inoculated with B. burgdorferi (10
5 spirochetes/mouse). B.
burgdorferi levels were measured by quantitative PCR from skin,
heart and joint samples collected at 7, 12, 15 and 30 days after
infection. Results indicated no significant difference in spirochete
burden between mice immunized with BbCRASP-2 or the control
at any time points (Fig. 2C). Quantitative RT-PCR analysis
further showed no difference between the transcript levels of
BbCRASP-2 in immunized and control groups (data not shown).
Figure 1. Ubiquitous expression of BbCRASP-2 in infected mice.
The relative expression levels of BbCRASP-2 in the murine host, and in
representative life stages of ticks, are analyzed and presented as copies
of BbCRASP-2 transcript per 1000 copies of flaB transcripts. Total RNA
was isolated from multiple tissues of B. burgdorferi-infected mice (6
mice/group) at day 5, 7, 12, 16 and 24 following challenge, from
infected fed larva (FL) after 3 days of feeding, unfed nymphs following
larval molting (UN) and fed nymphs (FN) after 3 days of feeding.
BbCRASP-2 transcripts were measured using quantitative RT-PCR. Error
bars represent the mean 6 SEM from four quantitative PCR analyses of
two independent murine infection experiments. BbCRASP-2 transcripts
were abundant in all murine tissues tested but were not detected in any
stages of the ticks.
doi:10.1371/journal.pone.0003010.g001
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influence the ability of B. burgdorferi to establish infection.
Development of ankle swelling (Fig. 2D) or histopathological
changes in the joint tissue (data not shown) in B. burgdorferi-infected
mice immunized with BbCRASP-2 did not differ from the control,
suggesting that host BbCRASP-2 antibodies fail to influence the
ability of B. burgdorferi to induce arthritis in the murine host.
Generation of an infectious isolate of BbCRASP-2-
deficient B. burgdorferi
Since BbCRASP-2 immunization did not influence spirochete
infection, we created a BbCRASP-2-deficient B. burgdorferi to more
directly assess the role of the gene product in B. burgdorferi survival
and infectivity. An infectious isogenic mutant was created by
replacing the BbCRASP-2 open reading frame with a kanamycin
resistance cassette via homologous recombination (Fig. 3A). PCR
analysis was performed to ensure that the antibiotic cassette was
appropriately inserted into the intended chromosomal locus
(Fig. 3B), and that the plasmid profile of the mutant was
unchanged. Out of 4 transformed clones that grew in antibiotic-
containing media, 2 clones contained the desired integration of the
antibiotic cassette and retained the same set of plasmid as in the
parental isolate. One of the mutant clones was chosen for further
study. RT-PCR analysis showed that BbCRASP-2 mRNA was
absent in the mutant (Fig. 3C), and that BbCRASP-2 mutagenesis
Figure 2. BbCRASP-2 immunization does not interfere with B. burgdorferi infectivity. A, Recognition of recombinant and native BbCRASP-2
proteins by immunized murine serum, as assessed by immunoblotting. Recombinant BbCRASP-2 protein (50 ng) or B. burgdorferi lysates (200 ng)
were probed with BbCRASP-2 antiserum or normal mouse serum (NMS). The arrow indicates the position of BbCRASP-2. Migration of protein
standards is shown to the left. B, BbCRASP-2 is not sensitive to proteinase K-mediated degradation of B. burgdorferi surface proteins. Viable
spirochetes (2610
8 cells) were incubated with (+) or without (2) proteinase K for removal of protease sensitive surface proteins and processed for
immunoblot analysis using BbCRASP-2 antibodies. B. burgdorferi OspA and FlaB antibodies were utilized as controls for surface-exposed and sub-
surface proteins, respectively. C, Comparable levels of B. burgdorferi in rBbCRASP-2-immunized or control mice. Groups of mice (6 animals/group)
were immunized with either rBbCRASP-2 or PBS (control) mixed with adjuvant, and 10 days after final immunization mice were infected with B.
burgdorferi (10
5 spirochetes/mouse). The spirochete burdens in both groups of mice were assessed by measuring copies of the B. burgdorferi flaB
gene at 7, 12 and 30 days following infection. Amounts of murine ß-actin were determined in each sample and used to normalize the quantities of
spirochete RNA. Bars represent the mean measurements 6 SEM from four quantitative PCR analyses from two independent infection experiments.
Levels of B. burgdorferi were similar in BbCRASP-2-immunized (black bars) and control mice (white bars). The burdens found in BbCRASP-2-immunized
mice were not statistically significant from the control burdens in any tissue or time point (P.0.05, n=4). D, Severity of joint swelling in BbCRASP-2-
immunized and infected mice. Groups of mice (6 animals/group) were immunized with BbCRASP-2 (black bars) or PBS (control, white bars) and
infected with B. burgdorferi. Development of joint swelling was assessed after 12 and 30 days of spirochete challenge by measuring the largest
diameter of the rear tibiotarsal joints using a digital caliper.
doi:10.1371/journal.pone.0003010.g002
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genes, bbh05 and bbh07 (data not shown). The BbCRASP-2 mutant
spirochetes displayed a similar protein profile to that of the wild
type (Fig. 3D, left panel), except that the BbCRASP-2 mutant failed
to produce BbCRASP-2 protein (Fig. 3D, upper right panel).
BbCRASP-2-deficiency did not affected serum resistance
of B. burgdorferi in vitro
B. burgdorferi is known to be resistant to complement-mediated
lysis in serum, and deficiency of BbCRASP-1 has been shown to
render B. burgdorferi highly susceptible to serum-mediated killing in
vitro [25]. Because BbCRASP-2 is expressed by wild type
spirochetes grown in culture, we assessed whether BbCRASP-2
deficiency affects the serum resistance of the spirochetes. Equal
concentrations of wild type and BbCRASP-2 mutant B. burgdorferi
were separately incubated with human serum containing active
complement and the serum sensitivity of each isolate was assessed.
While the isogenic BbCRASP-1 mutant were readily killed within 1
hour of serum exposure, the viability of the BbCRASP-2 mutant did
not differ significantly from that of the wild type (Fig. 4) indicating
that BbCRASP-2 is not essential for B. burgdorferi resistance to
complement-mediated lysis in serum.
BbCRASP-2-deficient B. burgdorferi retain full murine
infectivity
To examine whether the lack of BbCRASP-2 influences B.
burgdorferi infectivity in a mammalian host, C3H mice were
infected with wild type or BbCRASP-2 mutant B. burgdorferi. Both
the mutant and wild type spirochetes were readily cultured from
ear and spleen tissues taken from mice 12 days after the inoculum
(data not shown). When nymphal ticks were allowed to feed on
infected mice, BbCRASP-2 mutant B. burgdorferi were able to
migrate into fed ticks at a similar level to the wild type spirochetes
(data not shown). Quantitative RT-PCR further showed that the
Figure 3. Construction and analysis of the BbCRASP-2 mutant B. burgdorferi. A, Schematic drawings of the wild type isolate (WT) and the
BbCRASP-2 mutant (M) at the BbCRASP-2 (bbh06) locus. Genes bbh02, bbh03, bbh04, bbh05, bbh07, bbh08 and bbh09 (white box arrows) and the
kanamycin-resistance cassette driven by the B. burgdorferi flaB promoter (flaB-Kan, black box arrow) are indicated. Primers P1-P4 (black arrow-heads)
amplified 59 and 39 arms for homologous recombination, regions flanking up- and down-stream of the BbCRASP-2 locus and ligated on either side of
the flaB-Kan cassette as detailed in the text. B, Integration of the mutagenic construct, flab-Kan, in the intended genomic locus. Primers 5–12 (gray
arrow-heads, positions indicated in Fig. 3A) were used for PCR analysis using isolated DNA from wild type (WT) or BbCRASP-2 mutant B. burgdorferi (M)
and subjected to gel electrophoresis. The combination of primers used for PCR is indicated at the top. Migration of DNA ladder is shown on the left. C,
RT-PCR analysis of BbCRASP-2 transcripts. Total RNA was isolated from either the wild type (WT) or BbCRASP-2 mutant (M) B. burgdorferi, converted to
cDNA and used to PCR-amplify regions within BbCRASP-2 and flaB, and these amplicons visualized on a gel. D, Protein analysis of wild type (WT) or
BbCRASP-2 mutant (M) B. burgdorferi. Equal amounts of protein from wild type or BbCRASP-2 mutant spirochetes were separated on an SDS-PAGE gel,
and either stained with coomassie blue (left panel) or transferred onto a nitrocellulose membrane and probed with BbCRASP-2 or FlaB antibodies.
Migration of protein standards is shown to the left in kDa.
doi:10.1371/journal.pone.0003010.g003
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levels to the parental isolate. No significant differences in the
burdens of BbCRASP-2 mutant and wild type isolates were
detected in murine skin, heart and joint samples isolated after 7,
12 and 18 days of infection (Fig. 5). Development of swelling in the
murine joints infected with either the BbCRASP-2 mutant or the
wild type B. burgdorferi was also similar (data not shown). Overall,
these results suggest that BbCRASP-2 is not essential for
establishment of B. burgdorferi infection in the mouse model of
Lyme disease.
Loss of BbCRASP-2 function is not compensated by
augmented or new expression of other BbCRASPs
BbCRASP-2 deficiency did not affect the ability of the
BbCRASP-2 mutant to survive complement-mediated lysis in vitro
or establish infection in a mammalian host in vivo. Since B.
burgdorferi encodes multiple BbCRASPs that are capable of binding
host complement regulators, we explored the possibility that the
loss of BbCRASP-2 could be compensated by altered expression of
other potential BbCRASP genes, such as BbCRASP-1, -3 and -5.W e
did not examine the expression of BbCRASP-4, as the parental B.
burgdorferi isolate A3[36] lacks the non-essential cp32-2 plasmid
housing the gene. To examine BbCRASP expression, groups of 6
C3H mice were needle-inoculated with wild type or BbCRASP-2-
deficient B. burgdorferi (10
5 spirochetes/mouse). Infected murine
skin and heart samples were isolated 7, 12 and 18 days after
infection, and expression of each BbCRASP was measured by
quantitative RT-PCR. In vitro expression of BbCRASP genes was
also assessed by growing wild type and mutant B. burgdorferi in BSK
medium to various cell densities (10
6–10
8 spirochetes/ml) and
analyzed by quantitative RT-PCR. The expression profiles of
BbCRASP-1, -3, and -5 remained unaltered in the BbCRASP-2
mutant when compared to the wild type spirochetes, both in vitro
and in vivo, such as in the murine skin and heart tissues at all time
points. BbCRASP expression in cultured spirochetes grown in vitro
to a density of 10
7/ml and in infected murine skin and heart tissue
samples at 12 days of infection is presented (Fig. 6). These results
suggest that the loss of BbCRASP-2 function is not compensated
by alteration or new expression of other BbCRASP genes (Fig. 6).
Discussion
B. burgdorferi express up to five BbCRASPs that are either
structurally unique, such as BbCRASP-1 and -2, or closely related,
BbCRASP-3, -4 and -5 [17,18,21,45]. These BbCRASPs are
differentially expressed and are postulated to confer defense
against host-derived complements via specific interaction with FH
family proteins [16,17,31,32]. The precise role of individual
BbCRASPs in the B. burgdorferi infection cycle, however, is
currently unclear. BbCRASP-2 is specifically produced in the
mammalian host including humans, and is immunogenic, and
thus, is thought to be important in spirochete pathogenesis and
may be useful in a future Lyme disease vaccine [17,35]. Here, we
show that BbCRASP-2 is ubiquitously expressed throughout
murine infection, evoking a detectable antibody response.
However, BbCRASP-2 immunization fails to protect the host
against B. burgdorferi infection or influence the genesis of disease.
Targeted deletion of BbCRASP-2 did not impair the ability of the
mutants to resist serum-mediated killing in vitro, establish infectivity
in vivo, or the severity of disease. Deficiency of BbCRASP-2
expression in mutants is not functionally compensated by the
enhanced expression of other BbCRASP genes. BbCRASP-2,
therefore, is not essential for B. burgdorferi survivability in vitro, and
based on the time periods covered in the present study, we
conclude that BbCRASP-2 function is dispensable for B. burgdorferi
infectivity mice and in feeding ticks.
Immunization of murine hosts against specific B. burgdorferi
antigens, such as DbpA [46,47], OspC [48] and OspA [49] can
elicit production of borreliacidal antibodies, and thus confer
protective host immunity possibly by killing spirochetes in vivo
when administered prior to spirochete infection. In contrast, other
Figure 4. BbCRASP-2 mutant B. burgdorferi is resistant to
complement-mediated killing in vitro. Triplicate wells of spiro-
chetes (5610
6 cells/ml) were exposed to 50% normal human serum or
50% heat-inactivated human serum (HI) and the viability of B.
burgdorferi was assessed using dark-field microscopy. An isogenic B.
burgdorferi BbCRASP-1 mutant served as a serum-sensitive positive
control, which were killed within 1 hour of incubation with complement
active serum as expected (P,0.05, compared to corresponding HI
control), while both wild type and BbCRASP-2 remained fully resistant to
serum (P.0.05).
doi:10.1371/journal.pone.0003010.g004
Figure 5. BbCRASP-2 mutant B. burgdorferi retain full pathoge-
nicity in the murine host. The B. burgdorferi burdens in multiple
tissues of the infected mice are shown. Mice (6 animals/group) were
infected with either the wild type or the BbCRASP-2 mutant B.
burgdorferi and spirochete burdens were analyzed as before by
measuring copies of B. burgdorferi flaB RNA at day 7, 12 and 18
following infection. Amounts of murine ß-actin were determined in
each sample and used to normalize the quantities of spirochete RNA.
Bars represent the mean measurements 6 SEM from four quantitative
PCR measurements from two independent infection experiments. No
difference between wild type and BbCRASP-2 mutant levels was
statistically significant in any tissue or time point measured (P.0.05,
n=4).
doi:10.1371/journal.pone.0003010.g005
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Arp [50,51], that fail to protect host against B. burgdorferi infection,
but influence pathogenesis either by reduction of the B. burgdorferi
burden in selected tissues [13] or by modifying the disease without
affecting spirochete load [50,51]. The failure of BbCRASP-2-
specific host immunity to influence B. burgdorferi pathogenesis
indicates that BbCRASP-2 antibodies lack significant neutralizing
effects on spirochetes, possibly due to the lack of significant
surface-exposure of the antigen. This is further confirmed by the
observation that the BbCRASP-2-deficient B. burgdorferi displayed
no phenotypic defects in their ability to infect the murine host or
induce disease. Nevertheless, as BbCRASP-2 is abundantly
produced by B. burgdorferi throughout infection and evokes
development of specific antibody, our data reinforces an earlier
contention that BbCRASP-2 could be a reliable marker for the
serodiagnosis of Lyme disease [17,35].
B. burgdorferi expresses select lipoproteins [19] in the mammalian
host [52], including BbCRASP-2. Owing to its ubiquitous
expression in the host and known affinity for FH family proteins
[17], BbCRASP-2 appears to be important for B. burgdorferi
protection against persistent host immune threats, such as
complement system. BbCRASP-2 is conserved among infectious
B. burgdorferi isolates, which also suggests an important role for this
protein in the infectivity of B. burgdorferi [22]. The plasmid lp28-3
that houses BbCRASP-2 is retained in most of the B. burgdorferi
clones isolated from experimentally infected hosts [53–56].
Previous studies attempting to identify specific plasmids required
for B. burgdorferi infectivity indicate that lp28-3 plasmid may not be
strictly necessary for spirochete infectivity [55] while other studies
suggest that several plasmids, including lp28-3, in the correct
combinations, may be required to mediate B. burgdorferi infection of
the mammals [54]. Nevertheless, our data conclusively show that
the function of BbCRASP-2 is not essential for B. burgdorferi
survival against serum-mediated killing in vitro or host infectivity.
The BbCRASP-2 mutant fails to produce both BbCRASP-1 and
BbCRASP-2 in the murine host, yet still retains full infectivity,
which suggests that complement evasion in the host, if relevant,
could be mediated by BbCRASP-3 and -5, which remain fully
expressed by the mutant. Alternatively, binding to certain FH
family proteins may not be essential to the spirochetes, as previous
studies indicate that B. burgdorferi are able to infect and cause
disease in FH-deficient mice [57].
In summary, we present direct evidence that B. burgdorferi adapts
for the loss of a differentially expressed and abundant lipoprotein
during mammalian infection. Past studies also identified additional
B. burgdorferi genes encoding potential lipoproteins, such as BBA64
[58,59] or OspD [60,61] that display highly regulated expression
in vivo but lack an essential role in B. burgdorferi persistence in tick-
mouse infection cycle. Here we show that BbCRASP-2 function is
also dispensable for infectivity of the murine hosts or in feeding
ticks. Together, these results highlight B. burgdorferi as a unique
pathogen that has evolved versatile adaptive strategies to survive
and establish infection in a diverse array of host species, including
humans.
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